Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see what the effects of using one or two additional diabetes
drugs (dapagliflozin and exenatide-LAR) are on blood sugar levels in patients who are taking
insulin. This research study is being done to investigate which of these commonly-used
medications, medication combinations or increasing insulin dose is better.